CRISPR 基因编辑市场：当前分析和预测 (2022-2028)

由于对新治疗药物的需求不断增长，CRISPR 基因编辑市场预计将以 18% 左右的速度稳定增长。 CRISPR 基因编辑市场竞争激烈，有许多现有和新进入者。 市场上的主要参与者包括 Editas Medicine、CRISPR Therapeutics、Intellia Therapeutics 和 Caribou Biosciences。 这些公司提供各种 CRISPR 基因编辑产品和服务，包括研发、临床试验和商业化。 例如，2020 年 10 月，CRISPR Therapeutics 宣布启动一项新的基因编辑计划，用于治疗遗传性视网膜疾病 (IRD)。 该计划旨在使用 CRISPR-Cas9 基因编辑来靶向和纠正导致失明的 IRD 的基因突变。

根据产品类型，市场分为 CRISPR 产品和 CRISPR 服务。 其中，由于对基因工程技术的需求不断增加以及包括 CRISPR 基因编辑试剂盒在内的众多尖端技术的发展，预计 CRISPR 产品类别在预测期内将实现高复合年增长率。 此外，可用于实现各种目标的增强型单个产品的可用性，例如更容易的基因敲除、选择性基因组切割、减少脱靶切割、基因组工程和高特异性，这解释了该细分市场的增长。

按应用分为农业、生物医学（基因治疗、药物发现、诊断）、工业和其他。 其中，生物医药品类在2021年将占据较大的市场份额。 生物医药行业是最早采用CRISPR基因编辑技术的行业之一。 这是因为技术有可能彻底改变遗传疾病的治疗方法。 此外，增加对 CRISPR 基因编辑技术研发的投资、早期采用和严格的监管标准使生物医药领域成为该领域增长的主要驱动力。

按最终用户划分，CRISPR 基因编辑市场分为学术机构和研究中心、生物技术公司、合同研究组织 (CRO) 以及製药和生物製药公司。 预计在预测期内，製药和生物製药类别将主导 CRISPR 基因编辑市场。 这主要是由于我们在药物开发方面的专业知识，包括临床前和临床阶段，我们在研发方面的大量投资以开发新疗法，包括基于 CRISPR 的疗法，以及基于 CRISPR 的新疗法的成功开发。製药和生物製药公司已经建立了分销可以支持该细分市场增长的网络。

为了更好地了解 CRISPR 基因编辑行业的市场采用情况，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利、其他地区）欧洲）、亚太地区（（中国、日本、印度和亚太地区其他地区），以及在其他地区国家的全球业务。 在预测期内，北美预计将以显着的复合年增长率增长。 这主要是由于该地区发达的医疗基础设施和高技能的劳动力，为 CRISPR 基因编辑技术的开发和商业化提供了有利的环境。 该地区强大的研究生态系统，包括许多着名的学术研究机构，也为北美 CRISPR 基因编辑市场的增长做出了贡献。

内容

第一章市场介绍

• 市场定义
• 主要目的
• 利益相关者
• 限制

第 2 章研究方法或假设

• 研究过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对 CRISPR 基因编辑市场的影响

第 6 章 CRISPR 基因编辑市场收入，2020-2028F

第 7 章产品类型的市场洞察

• CRISPR 产品
  • 试剂盒和□
  • 图书馆
  • 设计工具、抗体
  • 其他
• CRISPR 服务
  • gRNA 设计和载体构建
  • 细胞系和工程
  • 筛选服务
  • 其他

第 8 章市场洞察：按应用

• 农业
• 生物医学（基因疗法、药物发现、诊断学）
• 工业
• 其他

第 9 章市场洞察：最终用户

• 学术机构和研究中心
• 生物技术公司
• 委託研究组织 (CRO)
• 製药和生物製药公司

第 10 章市场洞察：按地区

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地方

第 11 章 CRISPR 基因编辑市场动态

• 市场驱动力
• 市场挑战
• 影响分析

第 12 章 CRISPR 基因编辑市场机会

第13章CRISPR基因编辑市场趋势

第14章需求侧与供给侧分析

• 需求方分析
• 供应方分析

第 15 章价值链分析

第16章价格分析

第 17 章战略洞察

第 18 章衝突场景

• 竞争格局
  • 波特的五力分析

第十九章公司简介

• CRISPR Therapeutics
• Thermo Fisher Scientific Inc.
• Synthego
• System Biosciences, LLC
• ToolGen, Inc.
• Agilent Technologies, Inc.
• Merck KGaA
• Applied StemCell
• GeneCopoeia, Inc.
• Cellecta, Inc.

第20章 免责事项

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing is a revolutionary new technology that allows scientists to precisely modify genes in living organisms. This technology has the potential to revolutionize the field of medicine and provide new treatments for a range of diseases and medical conditions, including genetic disorders, cancer, and infectious diseases. The market for CRISPR gene editing is growing rapidly, driven by the increasing demand for new and effective treatments for various diseases and conditions, as well as the growing interest in precision medicine and personalized treatments. The market is also being driven by advancements in the technology itself, which are making it increasingly accessible and cost-effective for researchers and companies to use.

The CRISPR gene editing market is expected to grow at a steady rate of around 18% owing to the growing need for novel therapeutics. The CRISPR gene editing market is highly competitive, with many established players and new entrants. Key players in the market include Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences. These companies offer a range of CRISPR gene editing products and services, including research and development, clinical trials, and commercialization. For instance, in October 2020, CRISPR Therapeutics announced the launch of a new gene-editing program for the treatment of inherited retinal diseases (IRDs). The program aims to use CRISPR-Cas9 gene editing to target and correct mutations in the genes responsible for IRDs, which can cause blindness

Based on product type, the market is segmented into CRISPR products and CRISPR services. Among these, the CRISPR products category is to witness higher CAGR during the forecast period owing to the rising demand for genetic engineering technologies, and the development of a large number of cutting-edge technologies, including CRISPR gene editing kits. Additionally, the availability of enhanced individual products that can be used to achieve a variety of goals, such as simpler gene knockouts, selective genome cleavage, less off-target cutting, genome engineering, and higher specificity, is accountable for the growth of this segment.

On the basis of application, the market is categorized into agricultural, biomedical (gene therapy, drug discovery, and diagnostics), industrial, and others. Among these, the biomedical category held a significant share of the market in 2021. The biomedical industry has been one of the earliest adopters of CRISPR gene editing technology. This is because technology has the potential to revolutionize the treatment of genetic disorders and diseases. Furthermore, growing investment in research and development in CRISPR gene editing technology, early adoption, and strict regulatory standards has made the biomedical category a key driver in the growth of the segment.

Based on end-user, the CRISPR gene editing market has been classified into academic institutes & research centers, biotechnology companies, contract research organizations (CROs), and pharmaceutical & biopharmaceutical companies. The pharmaceutical & biopharmaceutical companies category is expected to dominate the CRISPR gene editing market during the forecast period. This is mainly due to expertise in drug development, including the preclinical and clinical phases, large investment in research and development to develop new therapies, including CRISPR-based treatments, they have the necessary expertise in regulatory compliance, manufacturing, commercialization to successfully launch new CRISPR-based therapies, and pharmaceutical and biopharmaceutical companies have established distribution networks that can boost the growth of this segment.

For a better understanding of the market adoption of the CRISPR gene editing industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the region having a well-developed healthcare infrastructure and a highly skilled workforce, providing a conducive environment for the development and commercialization of CRISPR gene editing technology. The region's strong research ecosystem, including many renowned academic and research institutions, also contributes to the growth of the CRISPR gene editing market in North America.

Some of the major players operating in the market include: CRISPR Therapeutics; Thermo Fisher Scientific Inc.; Synthego; System Biosciences, LLC; ToolGen, Inc.; Agilent Technologies, Inc.; Merck KGaA; Applied StemCell; GeneCopoeia, Inc.; Cellecta, Inc

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the CRISPR Gene Editing Market
• 2.2. Research Methodology of the CRISPR Gene Editing Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CRISPR GENE EDITING MARKET

6 CRISPR GENE EDITING MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. CRISPR Products
  • 7.1.1. Kits and Enzymes
  • 7.1.2. Libraries
  • 7.1.3. Design Tools, Antibodies
  • 7.1.4. Others
• 7.2. CRISPR Services
  • 7.2.1. gRNA Design and Vector Construction
  • 7.2.2. Cell Line and Engineering
  • 7.2.3. Screening Services
  • 7.2.4. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Agricultural
• 8.2. Biomedical (Gene Therapy, Drug Discovery, and Diagnostics)
• 8.3. Industrial
• 8.4. Others

9 MARKET INSIGHTS BY END-USER

• 9.1. Academic Institutes & Research Centres
• 9.2. Biotechnology Companies
• 9.3. Contract Research Organizations (CROs)
• 9.4. Pharmaceutical & Biopharmaceutical Companies

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 CRISPR GENE EDITING MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 CRISPR GENE EDITING MARKET OPPORTUNITIES

13 CRISPR GENE EDITING MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. CRISPR Therapeutics
• 19.2. Thermo Fisher Scientific Inc.
• 19.3. Synthego
• 19.4. System Biosciences, LLC
• 19.5. ToolGen, Inc.
• 19.6. Agilent Technologies, Inc.
• 19.7. Merck KGaA
• 19.8. Applied StemCell
• 19.9. GeneCopoeia, Inc.
• 19.10. Cellecta, Inc.

20 DISCLAIMER